Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pravastatin down-regulates inflammatory mediators in human monocytes in vitro

Grip, Olof LU ; Janciauskiene, Sabina LU and Lindgren, Stefan LU (2000) In European Journal of Pharmacology 410(1). p.83-92
Abstract

There is experimental evidence that pravastatin, which is designed to inhibit the rate-limiting enzyme of cholesterol synthesis, can affect cell metabolism and proliferation. We therefore studied the effects of pravastatin on the generation of inflammatory mediators in non-stimulated and stimulated primary human monocytes in vitro. In our experimental model, pravastatin induced a dose-dependent inhibition of monocyte cholesterol synthesis (up to 67%), up-regulation of low density lipoprotein receptor mRNA (by about 35%) and reduction in intracellular cholesterol accumulation. In parallel, exposure of non-stimulated monocytes to various doses of pravastatin resulted in inhibition of monocyte chemoattractant protein-1 protein expression... (More)

There is experimental evidence that pravastatin, which is designed to inhibit the rate-limiting enzyme of cholesterol synthesis, can affect cell metabolism and proliferation. We therefore studied the effects of pravastatin on the generation of inflammatory mediators in non-stimulated and stimulated primary human monocytes in vitro. In our experimental model, pravastatin induced a dose-dependent inhibition of monocyte cholesterol synthesis (up to 67%), up-regulation of low density lipoprotein receptor mRNA (by about 35%) and reduction in intracellular cholesterol accumulation. In parallel, exposure of non-stimulated monocytes to various doses of pravastatin resulted in inhibition of monocyte chemoattractant protein-1 protein expression (up to 15-fold), reduction of tumour necrosis factor alpha (TNF-α) levels (up to 2.4-fold) and a total loss of metalloproteinase-9 activity in stimulated cells. Pravastatin at concentrations of 5, 100 and 500 μM caused an inhibition of TNF-α-induced cellular oxygen consumption from 2.4- to 5.5-fold. These data extend the findings of potential anti-inflammatory actions of statins and also suggest the possibility for pravastatin use in a broader spectrum of inflammatory situations.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Inflammation, Lipid metabolism, Monocyte, Pravastatin, Pro-inflammatory molecule
in
European Journal of Pharmacology
volume
410
issue
1
pages
83 - 92
publisher
Elsevier
external identifiers
  • pmid:11134659
  • scopus:0034694774
ISSN
0014-2999
DOI
10.1016/S0014-2999(00)00870-0
language
English
LU publication?
yes
id
ebe4cafb-31b8-4c91-992c-1c4da0015e9b
date added to LUP
2019-08-07 13:29:56
date last changed
2024-03-03 21:58:39
@article{ebe4cafb-31b8-4c91-992c-1c4da0015e9b,
  abstract     = {{<p>There is experimental evidence that pravastatin, which is designed to inhibit the rate-limiting enzyme of cholesterol synthesis, can affect cell metabolism and proliferation. We therefore studied the effects of pravastatin on the generation of inflammatory mediators in non-stimulated and stimulated primary human monocytes in vitro. In our experimental model, pravastatin induced a dose-dependent inhibition of monocyte cholesterol synthesis (up to 67%), up-regulation of low density lipoprotein receptor mRNA (by about 35%) and reduction in intracellular cholesterol accumulation. In parallel, exposure of non-stimulated monocytes to various doses of pravastatin resulted in inhibition of monocyte chemoattractant protein-1 protein expression (up to 15-fold), reduction of tumour necrosis factor alpha (TNF-α) levels (up to 2.4-fold) and a total loss of metalloproteinase-9 activity in stimulated cells. Pravastatin at concentrations of 5, 100 and 500 μM caused an inhibition of TNF-α-induced cellular oxygen consumption from 2.4- to 5.5-fold. These data extend the findings of potential anti-inflammatory actions of statins and also suggest the possibility for pravastatin use in a broader spectrum of inflammatory situations.</p>}},
  author       = {{Grip, Olof and Janciauskiene, Sabina and Lindgren, Stefan}},
  issn         = {{0014-2999}},
  keywords     = {{Inflammation; Lipid metabolism; Monocyte; Pravastatin; Pro-inflammatory molecule}},
  language     = {{eng}},
  month        = {{12}},
  number       = {{1}},
  pages        = {{83--92}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Pharmacology}},
  title        = {{Pravastatin down-regulates inflammatory mediators in human monocytes in vitro}},
  url          = {{http://dx.doi.org/10.1016/S0014-2999(00)00870-0}},
  doi          = {{10.1016/S0014-2999(00)00870-0}},
  volume       = {{410}},
  year         = {{2000}},
}